BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 1, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» Gilead discloses GS-441524 prodrugs for treatment of viral infections
To read the full story,
subscribe
or
sign in
.
Infection
Gilead discloses GS-441524 prodrugs for treatment of viral infections
Nov. 19, 2024
No Comments
Gilead Sciences Inc. has synthesized 4-aminopyrrolo[2,1-F][1,2,4]triazine C-nucleoside analogues acting as prodrugs of GS-441524 and reported to be useful for the treatment of viral infections.
BioWorld Science
Infection
Patents